Phil Lambert, Ph.D., chief scientific officer, Satellos Bioscience, Part 3 скачать в хорошем качестве

Phil Lambert, Ph.D., chief scientific officer, Satellos Bioscience, Part 3

In this third segment of an interview with Managed Healthcare Executive, Phil Lambert, chief scientific officer for Satellos Bioscience Inc., discussed the clinical trials of its experimental treatnent for Duchenne muscular dystrophy. The treatment, named SAT-3247 for now, is a small-molecule drug that targets muscle stem cells with the intention of triggering the process that leads to muscle regeneration. Lambert described the results of a phase 1 dosing trial in healthy volunteers to assess safety as "very clean." Those results were presented in March 2025 at the MDA Clinical & Scientific Conference in March. On May 22, 2025, Satellos announced results of phase 1b that enrolled five men with Duchenne muscular dystrophy. The company's news release said the data from that trial showed that the drug was well tolerated and had the expected pharmacokinetics. Although not designed to assess efficacy, the news release says the data suggest early signs of improved grip strength. Lambert says the company is putting together its phase 2 program. "We are looking to be as time efficient as we can because we realize how important this is for patients."